Details

Autor(en) / Beteiligte

• Wiedenroth, Christoph B.
• Rolf, Andreas
• Steinhaus, Kristin
• Adameit, Miriam S.D.
• Kriechbaum, Steffen D.
• Haas, Moritz
• Roller, Fritz
• Hamm, Christian W.
• Ghofrani, H. Ardeschir
• Mayer, Eckhard
• Breithecker, Andreas
• Guth, Stefan
• Liebetrau, Christoph

Titel

Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension

Ist Teil von

• The Journal of heart and lung transplantation, 2023-01, Vol.42 (1), p.134-139

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The combination of riociguat and interventional balloon pulmonary angioplasty (BPA) is currently used to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The aim of the present study was to evaluate the impact of this combination therapy on the prognosis of inoperable CTEPH patients by comparing the long-term survival rates of patients undergoing combination therapy with riociguat and BPA with those of inoperable patients from the first international CTEPH registry who did not receive specific treatment. Between March 2014 and August 2019, 138 technically inoperable patients were included in the present prospective, observational cohort study when they were treated with riociguat and BPA at a single CTEPH referral center. Long-term survival of this cohort was compared using propensity score matching with that of inoperable patients recruited between 2007 and 2009 in the first international CTEPH registry. Kaplan-Meier methods were used to evaluate differences in outcomes. Whereas the survival rate in the historical group was 84.6% in the first year, 76.6% in the second, 68.5% in the third, and 58.5% in the fifth year after diagnosis, implementation of riociguat/BPA led to survival rates of 100%, 96.7%, 92.9%, and 90% in the respective follow-up periods. In a comparison of 83 well-matched pairs from the 2 cohorts, survival was markedly better in the group treated with riociguat and BPA than in the historical cohort (HR = 0.145, 95% CI 0.05, 0.421). The combination of riociguat and BPA for the treatment of inoperable CTEPH is associated with excellent 5-year survival rates.